Table 2.
ACH-702 antibacterial activity against Gram-positive clinical isolates
| Organism (no. of isolates)b | Antimicrobial | MIC (μg/ml)a |
||
|---|---|---|---|---|
| Range | MIC50 | MIC90 | ||
| Staphylococcus aureus (82) | ||||
| MSSA, all isolates (12) | ACH-702 | 0.015–1 | 0.03 | 0.25 |
| Levofloxacin | 0.12–>16 | 0.25 | >16 | |
| Oxacillin | 0.25–0.5 | 0.5 | 0.5 | |
| Linezolid | 2–2 | 2 | 2 | |
| Vancomycin | 1–2 | 1 | 2 | |
| MRSA, all isolates (70) | ACH-702 | 0.008–0.5 | 0.06 | 0.25 |
| Levofloxacin | 0.12–>16 | 16 | >16 | |
| Oxacillin | 4–>16 | >16 | >16 | |
| Linezolid | 1–2 | 1 | 2 | |
| Vancomycin | 0.5–2 | 1 | 1 | |
| MRSA, FQNS (49) | ACH-702 | 0.03–0.5 | 0.06 | 0.25 |
| Levofloxacin | 2–>16 | 16 | >16 | |
| Oxacillin | 4–>16 | >16 | >16 | |
| Linezolid | 1–2 | 2 | 2 | |
| Vancomycin | 0.5–2 | 1 | 1 | |
| Staphylococcus epidermidis | ||||
| All isolates (21) | ACH-702 | 0.015–0.25 | 0.03 | 0.25 |
| Levofloxacin | 0.12–>16 | 0.25 | >16 | |
| Oxacillin | 0.25–>16 | 1 | >16 | |
| Linezolid | 0.5–1 | 1 | 1 | |
| Vancomycin | 1–2 | 2 | 2 | |
| FQNS (9) | ACH-702 | 0.12–0.25 | 0.12 | 0.25 |
| Levofloxacin | 8–>16 | 16 | >16 | |
| Oxacillin | 0.25–>16 | 8 | >16 | |
| Linezolid | 0.5–1 | 1 | 1 | |
| Vancomycin | 1–2 | 2 | 2 | |
| Streptococcus pneumoniae | ||||
| All isolates (31) | ACH-702 | 0.015–0.06 | 0.03 | 0.06 |
| Levofloxacin | 0.5–2 | 1 | 1 | |
| Ceftriaxone | 0.015–8 | 0.5 | 1 | |
| Linezolid | 0.5–2 | 1 | 1 | |
| Penicillin | <0.015–8 | 1 | 4 | |
| PENNS (18) | ACH-702 | 0.03–0.06 | 0.03 | 0.06 |
| Levofloxacin | 0.5–2 | 1 | 2 | |
| Ceftriaxone | 0.5–8 | 1 | 2 | |
| Linezolid | 0.5–2 | 1 | 1 | |
| Penicillin | 0.25–8 | 4 | 4 | |
| Enterococcus faecalis | ||||
| All isolates (15) | ACH-702 | 0.06–0.5 | 0.25 | 0.5 |
| Levofloxacin | 0.5–>16 | >16 | >16 | |
| Linezolid | 0.5–>16 | 2 | >16 | |
| Vancomycin | 0.25–>32 | 1 | >32 | |
| FQNS (9) | ACH-702 | 1–2 | 1 | 1 |
| Levofloxacin | 16–>16 | >16 | >16 | |
| Linezolid | 0.5–>16 | 2 | >16 | |
| Vancomycin | 1–>32 | 1 | >32 | |
| Enterococcus faecium (14)c | ACH-702 | 0.25–4 | 1 | 2 |
| Levofloxacin | 4–>16 | >16 | >16 | |
| Linezolid | 0.5–>16 | 2 | 2 | |
| Vancomycin | 0.25–>32 | >32 | >32 | |
a
For current CLSI breakpoints for comparators, see reference 14.
b
FQNS, fluoroquinolone-nonsusceptible isolates as indicated by levofloxacin MICs relative to CLSI breakpoints; PENNS, penicillin-nonsusceptible isolates, including intermediate (I) and resistant (R) isolates.
c
All E. faecium isolates tested were fluoroquinolone resistant.